Last reviewed · How we verify
rAHF-PFM
At a glance
| Generic name | rAHF-PFM |
|---|---|
| Sponsor | Baxalta now part of Shire |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
- Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery (PHASE2, PHASE3)
- Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901 (PHASE2, PHASE3)
- Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A (PHASE4)
- Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients (PHASE3)
- Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection (PHASE1)
- Early Prophylaxis Immunologic Challenge (EPIC) Study (PHASE3)
- Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rAHF-PFM CI brief — competitive landscape report
- rAHF-PFM updates RSS · CI watch RSS
- Baxalta now part of Shire portfolio CI